temozolomide has been researched along with Diabetes Insipidus, Neurogenic in 3 studies
Diabetes Insipidus, Neurogenic: A genetic or acquired polyuric disorder caused by a deficiency of VASOPRESSINS secreted by the NEUROHYPOPHYSIS. Clinical signs include the excretion of large volumes of dilute URINE; HYPERNATREMIA; THIRST; and polydipsia. Etiologies include HEAD TRAUMA; surgeries and diseases involving the HYPOTHALAMUS and the PITUITARY GLAND. This disorder may also be caused by mutations of genes such as ARVP encoding vasopressin and its corresponding neurophysin (NEUROPHYSINS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Temozolomide is an oral DNA-alkylating agent capable of crossing the blood-brain barrier and used as chemotherapy primarily to treat glioblastoma and other brain cancers." | 8.02 | Central diabetes insipidus induced by temozolomide: A report of two cases. ( Capes, A; Duck, L; Duprez, T; Labriola, L; Mahiat, C; Whenham, N, 2021) |
| "Temozolomide (TMZ) is an alkylating agent primarily used to treat tumors of the central nervous system." | 5.39 | Central diabetes insipidus: a previously unreported side effect of temozolomide. ( Faje, AT; Klibanski, A; Makimura, H; Miller, KK; Nachtigall, L; Wexler, D, 2013) |
| " Temozolomide is an oral DNA-alkylating agent capable of crossing the blood-brain barrier and used as chemotherapy primarily to treat glioblastoma and other brain cancers." | 4.02 | Central diabetes insipidus induced by temozolomide: A report of two cases. ( Capes, A; Duck, L; Duprez, T; Labriola, L; Mahiat, C; Whenham, N, 2021) |
| "Temozolomide (TMZ) is an alkylating agent primarily used to treat tumors of the central nervous system." | 1.39 | Central diabetes insipidus: a previously unreported side effect of temozolomide. ( Faje, AT; Klibanski, A; Makimura, H; Miller, KK; Nachtigall, L; Wexler, D, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kuo, C | 1 |
| Foon, D | 1 |
| Waters, K | 1 |
| Cheung, C | 1 |
| Margol, AS | 1 |
| Mahiat, C | 1 |
| Capes, A | 1 |
| Duprez, T | 1 |
| Whenham, N | 1 |
| Duck, L | 1 |
| Labriola, L | 1 |
| Faje, AT | 1 |
| Nachtigall, L | 1 |
| Wexler, D | 1 |
| Miller, KK | 1 |
| Klibanski, A | 1 |
| Makimura, H | 1 |
3 other studies available for temozolomide and Diabetes Insipidus, Neurogenic
| Article | Year |
|---|---|
Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Diabetes Insipidus, Neurogenic; Humans; M | 2020 |
Central diabetes insipidus induced by temozolomide: A report of two cases.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Deamino Arginine Vasopressin; Diabetes In | 2021 |
Central diabetes insipidus: a previously unreported side effect of temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Diabetes Insipi | 2013 |